biotech / news / / The Manila Times
Wegovy® 7.2 mg in a single-dose pen has now been recommended by CHMP for approval in the EU.
CHMP has recommended approval of Wegovy 7.2 mg single-dose pen for obesity in the EU.
KEY POINTS
- Novo Nordisk plans to launch Wegovy 7.2 mg single-dose pen in the EU in Q3 2026.
- STEP UP trial showed Wegovy 7.2 mg achieved 20.7% mean weight loss with one-third exceeding 25%.
- Wegovy 7.2 mg single-dose pen is already available in the US and UK under Wegovy HD branding.
- In STEP UP T2D, Wegovy 7.2 mg led to 14.1% weight loss for patients with type 2 diabetes.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →